$VITR #Vitrolife AB Vitrolife - Q2 looks dark, but we see recovery in ‘21: Q1 sales and EBITDA +4% vs. ABGSCe We forecast -40% organic growth in Q2 EV/EBIT 34x reflects recovery in ‘21 https://t.co/g8GJoaB4kd #equity #stocks https://t.co/iw3IN5ikqH